Skip to content
ChickenStockChickenStock
ResearchTXG
10X Genomics logo

10X Genomics (TXG) stock

NASDAQ

$58.15-1.61%(-0.95)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-112.49x

Net loss — not comparable

P/B

9.13x

P/S

12.36x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 1.3% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 6, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

31 SEC filings
  • Saxonov SergeChief Executive Officer · Nov 10, 2026Open-market sale31,000 shares · $1.9M
    Avg. price $62.91,019,249 shares held after
  • Saxonov SergeChief Executive Officer · Sep 22, 2026Open-market sale25,000 shares · $2.0M
    Avg. price $81.2225
    Show 5 price lots
    • 9,900 shares × $81.8254$810K
    • 9,300 shares × $80.9033$752K
    • 2,800 shares × $82.365$231K
    • 2,000 shares × $79.6195$159K
    • 1,000 shares × $78.2284$78K
  • SULIMAN SHEHNAAZDirector · Sep 22, 2026Open-market sale5,723 shares · $465K
    Avg. price $81.1931
    Show 5 price lots
    • 2,270 shares × $81.6699$185K
    • 1,325 shares × $80.8164$107K
    • 1,222 shares × $82.2768$101K
    • 614 shares × $79.5114$49K
    • 292 shares × $78.1959$23K
  • Taich AdamChief Financial Officer · Sep 9, 2026Open-market sale46,388 shares · $3.0M
    Avg. price $64.5743
    Show 3 price lots
    • 31,428 shares × $64.3097$2.0M
    • 13,754 shares × $65.2574$898K
    • 1,206 shares × $63.6774$77K
  • STUELPNAGEL JOHN RDirector · Sep 3, 2026Open-market sale20,000 shares · $1.2M
    Avg. price $61.7536
    Show 3 price lots
    • 7,012 shares × $60.6579$425K
    • 6,814 shares × $62.1082$423K
    • 6,174 shares × $62.6066$387K
  • Saxonov SergeChief Executive Officer · Sep 1, 2026Gift100 shares · $0
    Avg. price $01,075,249 shares held after
  • Saxonov SergeChief Executive Officer · Aug 26, 2026Open-market sale10,486 shares · $668K
    Avg. price $63.6945
    Show 3 price lots
    • 6,494 shares × $63.9768$415K
    • 3,500 shares × $63.0229$221K
    • 492 shares × $64.7465$32K
  • Saxonov SergeChief Executive Officer · Aug 24, 2026Open-market sale18,545 shares · $1.2M
    Avg. price $63.02371,085,835 shares held after
  • Taich AdamChief Financial Officer · Aug 24, 2026Open-market sale17,166 shares · $1.1M
    Avg. price $63.023362,732 shares held after
  • Hindson Benjamin J.See Remarks · Aug 24, 2026Open-market sale13,818 shares · $871K
    Avg. price $63.0236488,182 shares held after
  • SULIMAN SHEHNAAZDirector · Aug 24, 2026Open-market sale2,207 shares · $140K
    Avg. price $63.6511
    Show 2 price lots
    • 1,646 shares × $63.9664$105K
    • 561 shares × $62.7259$35K
  • Saxonov SergeChief Executive Officer · Aug 20, 2026Gift4,000 shares · $0
    Avg. price $01,104,380 shares held after
  • Teichmann Sarah A.Director · Aug 14, 2026Open-market sale2,273 shares · $130K
    Avg. price $57.1528,058 shares held after
  • Teichmann Sarah A.Director · Aug 13, 2026Open-market sale5,278 shares · $302K
    Avg. price $57.2930,331 shares held after
  • STUELPNAGEL JOHN RDirector · Aug 11, 2026Open-market sale20,000 shares · $1.2M
    Avg. price $57.7528
    Show 2 price lots
    • 17,000 shares × $57.5812$979K
    • 3,000 shares × $58.725$176K

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

10X Genomics (TXG) stock information

NASDAQ

10X Genomics (TXG) is listed on NASDAQ. Its market capitalization is about $7.6B. On trailing-twelve-month earnings the P/E ratio is -112.49, and the P/B ratio is 9.13. Return on equity is -8.1%. These figures are computed in-house from official filings and are reference information only.

10X Genomics — frequently asked questions

What is the P/E ratio of 10X Genomics (TXG)?
On a trailing-twelve-month basis, TXG trades at a P/E ratio of -112.49. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of 10X Genomics?
TXG has a market capitalization of about $7.6B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.